Home Cell Therapy Athersys Stem Cell Therapy Targets Top Cause of COVID-19 Deaths

Athersys researchers__thumbnail_IMG_6708v2 — Athersys researchers involved in making MultiStem®, an adult-derived "off-the-shelf" stem cell product. Athersys says it is working as fast as it can to launch a pivotal trial of its in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from the Biomedical Advanced Research and Development Authority (BARDA). [Athersys]

Athersys Stem Cell Therapy Targets Top Cause of COVID-19 Deaths

Chairman and CEO Gil Van Bokkelen, PhD, Discusses BARDA’s “Highly Relevant” Designation for MultiStem with GEN

By Alex Philippidis

March 26, 2020

Athersys researchers involved in making MultiStem®, an adult-derived "off-the-shelf" stem cell product. Athersys says it is working as fast as it can to launch a pivotal trial of its in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from the Biomedical Advanced Research and Development Authority (BARDA). [Athersys]

Athersys says it is working as fast as it can to launch a pivotal trial of its MultiStem® adult-derived "off-the-shelf" stem cell product in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from BARDA. [Athersys . . .